Kimberly Blackwell - 16 May 2022 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role: President & CEO, Director
Signature: By: /s/ Melissa B. Epperly, Attorney-in-Fact for Kimberly Blackwell
Issuer symbol: ZNTL
Transactions as of: 16 May 2022
Net transactions value: $0
Form type: 4
Filing time: 20 May 2022, 16:27:31 UTC
Previous filing: 05 Jan 2022
Next filing: 10 Jun 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ZNTL	Stock Option (Right to Buy)	Award	$0	+1,708,809		$0.000000	1,708,809	16 May 2022	Common Stock	1,708,809	$24.41	Direct	F1
transaction	ZNTL	Stock Option (Right to Buy)	Award	$0	+427,202		$0.000000	427,202	16 May 2022	Common Stock	427,202	$24.41	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option vests and becomes exercisable as to 25% of the shares on May 16, 2023 and vests in equal monthly installments thereafter until May 16, 2026.
F2	The option vests and becomes exercisable as to 100% of the shares on the earlier of (a) FDA approval of a Zentalis product or (b) a Change in Control (as defined in the Issuer's 2020 Incentive Award Plan).